12 June 2012 - C8 MediSensors Inc, a company involved in developing non-invasive, continuous glucose monitoring for people with diabetes, has announced today that it has raised an incremental USD19m from the sale of Preferred C-1 stock.

The funds will help the company to prepare for its new product launch in Europe.

C8 MediSensors' CEO, Paul Zygielbaum, said: 'Better diabetes management requires better glucose visibility to the patient. You can't control what you can't see. After years of research, development and clinical testing, we are thrilled to be on the verge of introducing our optical glucose monitor, which is designed to provide people like me with continuous visibility into their glucose levels throughout the day.'